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Abstract
Elevated iron in the SNpc may play a key role in Parkinson’s disease (PD) neurodegeneration since drug candidates
with high iron affinity rescue PD animal models, and one candidate, deferirpone, has shown efficacy recently in a
phase two clinical trial. However, strong iron chelators may perturb essential iron metabolism, and it is not yet
known whether the damage associated with iron is mediated by a tightly bound (eg ferritin) or lower-affinity, labile,
iron pool. Here we report the preclinical characterization of PBT434, a novel quinazolinone compound bearing a
moderate affinity metal-binding motif, which is in development for Parkinsonian conditions. In vitro, PBT434 was far
less potent than deferiprone or deferoxamine at lowering cellular iron levels, yet was found to inhibit iron-mediated
redox activity and iron-mediated aggregation of α-synuclein, a protein that aggregates in the neuropathology. In
vivo, PBT434 did not deplete tissue iron stores in normal rodents, yet prevented loss of substantia nigra pars
compacta neurons (SNpc), lowered nigral α-synuclein accumulation, and rescued motor performance in mice
exposed to the Parkinsonian toxins 6-OHDA and MPTP, and in a transgenic animal model (hA53T α-synuclein) of
PD. These improvements were associated with reduced markers of oxidative damage, and increased levels of
ferroportin (an iron exporter) and DJ-1. We conclude that compounds designed to target a pool of pathological
iron that is not held in high-affinity complexes in the tissue can maintain the survival of SNpc neurons and could
be disease-modifying in PD.
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Introduction
Idiopathic Parkinson’s disease (PD) is characterized by
loss of the neurons of the substantia nigra pars compacta
(SNpc) and the presence of intracellular Lewy bodies com-
posed primarily of fibrillar deposits of the synaptic protein
α-synuclein. The physiological function of α-synuclein is
poorly understood, but genetic evidence strongly impli-
cates this highly-expressed protein in the pathological
process in PD and other movement disorders such as
Multiple System Atrophy and Diffuse Lewy Body Disease,
(classified as synucleinopathies).
α-synuclein may be neurotoxic in the fibrillar state
or soluble oligomeric species [20, 42]. However, it is
expressed throughout the brain, so the selective vul-
nerability of the SNpc in PD indicates other local fac-
tors may be involved in toxicity. This could be due to
the co-localization within the SNpc of the chemical
reductant dopamine (DA) with an abundance of the
redox active metal iron, in addition to α-synuclein [41, 43].
α-synuclein binds iron with micromolar affinity [22], and
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both iron and DA promote the aggregation of α-synuclein
and the formation of Lewy bodies [15, 16, 28, 33], and can
react together to form damaging peroxides [40]. There is
consistent evidence of a regional increase of iron in the
SNpc of PD patients [10, 25, 64] as well as a rapid accumu-
lation of nigral iron in animals following intoxication with
the Parkinsonian agents 6-hydroxydopamine (6-OHDA)
and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
[27, 70]. Iron is needed for numerous catalytic and
metabolic processes including as a cofactor for tyrosine
hydroxylase (TH), the enzyme responsible for the produc-
tion of L-3,4-dihydroxyphenylalanine (L-DOPA) from
tyrosine [36, 85]. However, dysregulation of iron through
aging may increase the potential for oxidative damage
[11], which is exaggerated in the SNpc in PD [9].
Recently, the high affinity iron chelator deferiprone
(3-Hydroxy-1,2-dimethyl-4-pyridinone) was reported to
provide benefit in a phase 2 randomized clinical trial in
PD patients [24]. Although deferiprone was well toler-
ated there remain concerns with known adverse effects
of strong chelators [81]. Indeed, there is no certainty
about the compartment of pathological iron in the
SNpc that might mediate the neuropathology. Since the
labile iron pool is not tightly bound, we reasoned that
it might be possible to provide neuro-rescue with
moderate-affinity bioavailable iron chelators. We have
been developing candidate drugs for neurodegenerative
diseases designed to re-establish normal metal homeosta-
sis and abort the oligomerization of susceptible proteins
caused by pathological low affinity adventitial metal
ligation [1, 2, 18, 53, 57]. PBT434, an orally bioavailable
8-hydroxyquinazolin-4(3H)-one, binds iron sufficiently
to abolish pathological reaction with α-synuclein, but
with an affinity that is designed not to disrupt physio-
logical iron homeostasis.
We hypothesized that targeting the pathological pool
of nigral iron that emerges in these models with PBT434
would preserve function and the consequent accumula-
tion of α-synuclein. We tested PBT434 for its ability to
preserve neuronal viability and connectivity, motor func-
tion, α-synuclein accumulation and markers of oxidative
stress in three animal models of PD: the Parkinsonian
toxins 6-OHDA and MPTP, and hA53T transgenic mice
(which overexpress human α-synuclein bearing the ala-




Potentiometric titrations of the peptides were performed
on a MettlerTitrando 907/Dosino 800 titration system,
using InLab 422 combined glass-Ag/AgCl electrodes
(Mettler-Toledo), which were calibrated daily by nitric
acid titrations [2]. 0.1 M NaOH (carbon dioxide free)
was used as titrant. Sample volumes of 1.2–1.5 ml were
used. The samples contained typically 0.8 mM PBT-434,
dissolved in 4 mM HNO3/96 mM KNO3. The Fe (II)
and Fe (III) complex formation was studied using a 2.5–
4-fold excess of the compound over the metal ion, added
as nitrate. All experiments were performed under argon
at 25 °C, in the pH range of 2.3 to 12.2. The collected
data were analyzed using the HYPERQUAD program
[1]. Three to five titrations were included simultaneously
into calculations, separately for protonation, Fe (II) and
Fe (III) complexation.
The UV-visible spectra were recorded at 25 °C on a
Cary 50 or a Perkin Elmer spectrophotometer, over the
spectral range of 230–800 nm. The optical path for all
experiments was 1 cm. The samples containing PBT-434
alone or with Fe (II), Fe (III), Cu (II) or Zn (II) ions were
titrated with NaOH in the pH range of 2.0–12.0, by
careful manual additions of very small amounts of the
concentrated base solution. For Fe (III) and Fe (II) the
PBT-434 concentration used was 0.1 mM, and the
ligand-to-metal ratio was 4:1, to keep in line with condi-
tions that delivered good potentiometic titrations. For
Cu (II) the PBT434 concentration used was 0.1 mM, and
the ligand-to-metal ratios used varied between 1:1 and
4:1. For Zn (II) spectroscopic titrations were performed
at a lower concentration of 0.04 mM PBT434 and
0.02 mM Zn (II) to avoid precipitation. The Fe (II) sam-
ples were prepared under nitrogen, in a Coy glove box,
and transferred to the spectrophotometer [34, 46].
Inhibition of metal/dopamine mediated H2O2 generation
This technique, adapted from established protocols [74],
is a dicholorofluoroscein (DCF)-based fluorometric assay
that evaluates the ability of a test compound to inhibit
H2O2 generated by redox active metals in the presence
of a reducing agent.
α-synuclein aggregation assay
Each batch of recombinant α synuclein that was synthe-
sised underwent protein sequencing and mass spectrom-
etry to ensure purity at the Monash Protein Production
Unit (Monash University, Australia). The lyophilised
purified WT recombinant α synuclein was reconstituted
with Tris Buffer Saline (TBS) pH 7.4. Pooled aliquots
were spun at 100,000 g for 30 mins at 4° to remove pre-
formed aggregates/seeds. The supernant containing the
monomeric form was collected and used in the assay.
The protein concentration was determined using BCA
method Iron Nitrate was weighed and dissolved in TBS
solution. PBT434 was dissolved in 100% DMSO, then di-
luted to stock solution using milliQ water. To each tube,
TBS, Fe, Compound/Veh then α synuclein was added in
sequence with equal concentrations. The final concen-
tration of α synuclein, Fe and compound was 186.6 μM.
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Once all solutions were in the tubes, samples were
vortex for 2 s before plating up. Samples were assayed in
the presence of ThT (20 μM). The assay was read in a
Perkin-Elmer Enspire multi-mode plate reader set at 37°,
reading every 30 mins (1800 s), shaking at 800 rpm
(1800 Seconds) between each read up to 42 h. ThT fluor-
escence intensity was measured over time at wavelengths
450 emission and 485 nm excitation. The RFU values
were normalised to TBS ThT blank wells and were plot-
ted over time. The lag-time and the maximal relative
fluorescent units (RFU) were reported as a measure of
kinetic profiling of compounds. These were calculated
based on a 4-point parameter sigmoidal curve (plotted
in Sigmaplot V12.5).
Preparation of α-synuclein fibril samples for transmission
electron microscopy
Forty-two hours after initiating the α-synuclein reaction
20uL droplets were adsorbed onto formvar-coated copper
grids for 30 mins. After incubating the excess solution was
blotted away and the samples on grids were stained with
1% uranyl acetate for 30 s. The excess stain was then blot-
ted away and the grids allowed to dry at room temperature
overnight. The samples on grids were viewed in an FEI
Tecnai Spirit transmission electron microscope at 120 kV.
Images were captured with a Gatan Eagle digital camera at
a resolution of 2 K × 2 K pixels.
Iron efflux assay
M17 neuroblastoma cells were detached from two 175 cm
flasks and re-suspended in 100 ml of Optimem growth
medium. Cells were transferred to poly-d-lysine coated,
12-well plates and allowed to recuperate for 24 h. 50 μl of
59Fe was added to 800 μl of Optimem (without serum) for
overnight incubation. Cells were then washed in HBSS
(buffered saline) × 3, then 500 μl of HBSS was added with
either no drug 1 μM, 10 μM, 20 μM of PBT434 or deferi-
prone. Experiment was terminated after 3 h. Medium was
removed and radiation measured using a gamma counter.
Mice
Male C57BL/6 J mice aged 12 weeks and weighing ≈25 g
were used for the 6-OHDA and MPTP studies (Animal
Resources Centre; Western Australia). The hA53T Tg
mice were bred in-house (Jax Stock No: 004479; B6;C3-Tg
(Prnp-SNCA*A53T)83Vle/J; A53T α-synuclein transgenic
line M83). PBT434 (at 30 mg/kg/day) was delivered either
by oral gavage or by being mixed into rodent chow (Glen
Forrest Stockfeeds, Western Australia; spiked at 0.25 g/kg
food; 20 days days of treatment for the MPTP; 18 days of
treatment 6-OHDA; four months of daily treatment for
the hA53T Tg mice).
6-OHDA intoxication model
Mice anesthetized with 2.5–3% isoflurane were placed
into a stereotaxic apparatus and 3.0 μg of 6-OHDA was
injected into the right SNpc, as described in [77]. Am-
phetamine induced (5 mg/kg) rotational behavior was
measured three days after 6-OHDA lesion using an au-
tomated Rotacounter system (Columbus Instruments,
Columbus, OH, USA). Robust rotational behavior has
been observed as early as one-day post-lesion [82, 87].
Only mice that exhibited rotations at day 3 between 200
and 450 times per hour were included in the trial. Mice
were then randomly assigned to the PBT434 treatment
group or sham-vehicle (VEH) treatment group. The
PBT434 treatment group was gavaged at 30 mg/kg/day,
commencing 3 days following induction of lesion. Exper-
imenters were blinded to the assignment of treatments
for each of the groups. Mice were retested and then
culled twenty-one days post 6-OHDA lesion.
MPTP model
Mice were administered an acute dosing regimen of four
injections of MPTP (Sigma, USA) two hours apart
[4, 5, 61]. Each experimental trial contained MPTP le-
sioned animals that were randomly subdivided into a
sham treated group (vehicle alone) and drug treatment
group (30 mg/kg/day PBT434, commencing 24 h after
MPTP until culled at day 21). Experimenters were blinded
to the assignment of treatments for each of the groups. In
one group of animals the mice were treated with analog of
PBT434 (PBT434-met 30 mg/kg/day) which does not have
the ability to bind metals as a control.
The pole test was used to measure motor co-ordination
and performance at twenty days post MPTP injection
[32, 67, 73]. The mice were assessed on their ability to
rotate their heads and their bodies 180° to position
themselves in order to turn down descend down the
pole to the home cage [44]. The fastest times obtained
from the five trials were used as the value for turn time;
measured in seconds. Experimenters were blinded to
the treatments of each of the groups.
Hindlimb clasping and motor activity
Briefly, mice were suspended by the base of the tail and
their behaviors were recorded for 30 s [62, 78]. Spontan-
eous motor activity was measured in the hA53T α- synu-
clein mouse using an open field photo-beam activity
System (Truscan 2.0, Coulbourn Instruments, USA) [61].
Tissue preparation
At the completion of a trial, mice were killed with an
overdose of anesthetic, perfused with phosphate buffered
saline (PBS) pH 7.4 and tissues collected [61]. The blood
samples were analyzed by a veterinary pathology service
(Gribbles Veterinary Australia, accreditation to ISO/IEC
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17025 conferred by the National Association of Testing
Authorities and certification to AS/NZS 9001: 2008 con-
ferred by Lloyd’s Register Quality Assurance).
Western blots
Western blot was used to investigate protein expression
of human α- synuclein in the hA53T mouse (LB509;
1:10,000; Abcam, USA), the expression of endogenous
α- synuclein (97/8 1;10,000; a gift from Dr. Janetta Culve-
nor, University of Melbourne, Australia) or human, tyro-
sine hydroxylase (TH, 1:10,000; Millipore, USA), Protein
deglycase, also known as Parkinson disease protein 7 (DJ-
1, Polyclonal, 2134, CST, Boston, USA), Ferroportin-1
(1:1000; Santa Cruz, USA), Anti-synaptophysin, clone
SY38 (1:10,000; Millipore, USA), Samples were homoge-
nised in PBS buffer (PBS, Invitrogen, EDTA-free Protease
cocktail inhibitor, Roche, USA) with 11.02 mg/mL BHT
(Sigma-Aldrich, USA) in acetonitrile (Sigma-Aldrich,
USA) solution using sonication (20% amplitude, pulses 1–
2 s while on ice). The crude homogenate was spun on a
benchtop centrifuge for 10 mins 4 °C. Homogenate was
assayed for protein (Thermo Scientific Pierce BCA Protein
Assay Kit) and between 5 and 10 μg of protein loaded
onto NuPage Novex bis-tris 4–12% 26 well gels (Invitro-
gen, USA). Total protein was measured on the membrane,
with a ponceau stain (5 min at room temperature (0.1%
ready se stain, Sigma-Aldrich, catalogue # P7170). Excess
stain was washed from the membrane before exposing.
The ponceau stain was used to normalise the protein of
interest against total protein (loading control). The mem-
brane was imaged using a LAS-3000 [1, 61].
α -synuclein solubility analysis
Western blot for α- synuclein. Tissue samples were col-
lected, frozen, and stored at −80 °C for later use. Brain
homogenates were prepared by sequential extraction,
with the 5% SDS soluble and 8 M urea soluble fractions
examined by Western blot. Protein concentrations of
the initial brain homogenates were estimated using an
assay for bicinchoninic acid (BCA, Pierce Protein Assay
Kit, ThermoFisher Scientific, U.S.A.). Western blots
were probed with the α- synuclein antibody LB509
(Abcam, USA).
8-isoprostane ELISA
Dissected SN samples were collected, snap frozen and
stored at -80°C until analysis. The tissue homogenates
were analysed in the competitive ELISA as per the man-
ufactures instructions (Cayman Chemicals).
Metal analysis
Iron imaging of selected region (Substantia nigra; both
pars compacta and pars reticulata) was performed on the
30 μm cryostat sections using Laser ablation-inductively
coupled plasma-mass spectrometry (LA-ICPMS) on a
New Wave Research UP213 laser ablation unit (Kennelec
Scientific, Australia) coupled to an Agilent 7500ce ICP-
MS system (Mulgrave, Australia). The full methods
have been described previously [38, 59]. Additional iron
measurements were performed using liquid phase ICPMS
Varian UltraMass 700 (Varian, Australia) [12].
Stereology
The total number of DA neurons in the SNpc was esti-
mated using a fractionator sampling design [29, 61, 77].
Brains were fixed overnight in 4% paraformaldehyde in
PBS, then cryoprotected in 30% sucrose until the brains
sunk, the SNpc was sectioned in a 1 in 3 series at 30 μm
with a cryostat (Leica), stained with the TH antibody,
reacted with diamiobenzidine tetrahydrochloride (DAB;
Sigma) and counter stained with neutral red [17].
Counts were made at regular predetermined intervals
(x = 140 μm, y = 140 μm). Systematic samples of the
area occupied by the nuclei were made from a random
starting point. An unbiased counting frame of known
area (45 μm × 35 μm) was superimposed on the image
of the tissue sections using stereology software (MBF,
Stereo Investigator) utilizing a 63 × objective lens (Leica,
N.A.1.36). Experimenters were blinded to the treatments
of each of the groups. Every neuron within the SNpc
(TH – positive and negative) was counted to obtain an
estimate of neuronal number. The density of TH-
immunopositive varicosities was obtained from the
dorsal 400 μm of the caudate putamen (CPu) [30].
Cerebrospinal fluid collection from dogs
The collection of cerebrospinal fluid (CSF) was per-
formed at the conclusion of a 28 day toxicology study in
10 month old Beagle dogs undertaken at Charles River
Laboratories Preclinical services Edinburgh UK under
appropriate ethics approval. PBT434 was administered
by oral gavage once a day for 28 days at the following
doses: vehicle control (0 mg/kg/day), 10 mg/kg/day,
30 mg/kg/day and 50 mg/kg/day. Each treatment arm
included 3 male and 3 female dogs. The CSF was ex-
tracted at necropsy into collection tubes containing
10uL of butylated hydroxytoluene, frozen on dry ice and
stored at −80 °C until analysis. Any samples showing
signs of hemolysis were excluded due to the potential
for contamination of α-synuclein from blood [52].
Cerebrospinal fluid collection from rats
Cannulas were inserted into the lateral cerebral ventri-
cles of wild-type rats by stereotactic surgery. CSF sam-
pling was performed using a rodent microdialysis bowl
(BASi, n = 8). Baseline CSF was sampled after which
the animals were gavaged with PBT434 at 30 mg/kg.
CSF samples were collected at one and four hours after
Finkelstein et al. Acta Neuropathologica Communications  (2017) 5:53 Page 4 of 16
gavage with PBT434. Samples were analysed by Western
blot for the presence of α-synuclein as described.
Statistical analysis
SPSS version 17.0 (Windows version), was used for all
statistical analyses. Any significant differences in the
mean scores were denoted by asterisks throughout the
manuscript (* p < 0.05, ** p < 0.01 and *** p < 0.001).
Results
Affinity of PBT434 for metal ions
PBT434 was found to have a dissociation constant (Kd) for
Fe (III) and Cu (II) of ~10−10 M. The affinities for Fe (II)
and Zn were found to be ~10−5 M and ~10−7 M respect-
ively (Additional file 1: Data S1). Classical high affinity iron
chelators such as deferoxamine (Kd ≈ 10−31 M) and deferi-
prone (Kd ≈ 10−35 M) have been evaluated for their poten-
tial therapeutic use in iron overload conditions such as
thalassemia and in PD [24, 75]. As PBT434 has greater than
20 orders of magnitude less affinity for iron than these clas-
sical chelators, it was thought valuable to evaluate whether
the large difference in affinities might be reflected in the
ability of the respective compounds to promote the efflux
of Fe from biological tissues. Cultured neuronal M17 cells
were exposed to a trace quantity of the gamma emitting
iron isotope 59Fe and then to each compound over a range
of concentrations. At the highest concentration (20 μM)
PBT434 was shown to have a significant but ~5 fold lesser
ability to promote the flow of Fe out of cultured neuronal
M17 cells than 20 μM deferiprone (Fig. 1). When adminis-
tered to normal unlesioned mice, PBT434 at the dose of
30 mg/kg/day for 21 days had no significant effect on brain
iron levels or peripheral indices of iron trafficking and me-
tabolism (Additional file 1: Figure S2).
Inhibition of metal mediated redox activity
PBT434 was assessed for its ability to inhibit redox activ-
ity in an in vitro assay modeling an elevated dissociable
pool of metals in the presence of the potent reductant
dopamine (DA). Fe in the form of Fe (II)-citrate was in-
cubated with DA in aerated buffer, and H2O2 production
was assessed. PBT434 significantly inhibited H2O2 produc-
tion by iron (Fig. 1c). An analog of PBT434 (PBT434-met)
was synthesized in which the hydrogen of the phenolic
hydroxide substituent was replaced by a methyl group,
abolishing its ability to bind metals. The PBT434-met
analog was unable to suppress H2O2 production (Fig. 1c).
Iron mediated aggregation of α-synuclein
In an in vitro assay modeling iron-mediated acceleration
of α- synuclein aggregation, PBT434 significantly reduced
the rate of Fe-mediated aggregation of α-synuclein as
measured by the lag-time for the detection of fluorescent
aggregates compared with α-synuclein/Fe alone. In
Fig. 1 PBT434 enhances the release of iron and prevents the generation
of hydrogen peroxide. Cultured M17 neuroblastoma cells were loaded
with the iron isotope 59Fe. The cells were washed and then exposed to a
chelator to assess if iron could be removed from the cell. Cells loaded with
the iron isotope 59Fe were exposed to a PBT434 and the amount of
radioactive 59Fe released into the media was measured (CPM = counts per
minute) or b deferiprone at 0, 1, 10 or 20 μM for 3 h. Deferiprone showed
a dose related increase in the levels of 59Fe secreted into growth medium.
With PBT434 the effect was observed only at the highest dose of 20 μM
(*P < 0.05, ** P < 0.01, *** P < 0.0001, One-way ANOVA, Tukey Post Hoc).
At the highest concentration, the effect of deferiprone was 5-fold greater
than for PBT434. The dashed line represents equivalent values on the two
graphs. c PBT434 causes an inhibition of metal mediated redox activity.
Fe-citrate (0.4 μM) in the presence of dopamine (DA, 50 mM) generate
hydrogen peroxide (H2O2) assessed using a cell-free fluorescence-based
assay. PBT434 at 10 μM but not PBT434-met significantly reduced H2O2
generated by Fe/DA (PBT434-met = analog of PBT434 in which the metal
binding site is blocked; One-way ANOVA, Tukey Post Hoc). Dopamine
without Fe-Citrate did not produce H2O2
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contrast, PBT434-met did not inhibit the rate of Fe-
mediated aggregation (Fig. 2), consistent with the aggrega-
tion being caused by Fe coordination.
Neuroprotective effects of PBT434
Pharmacokinetic (PK) data showed that PBT434 was orally
bioavailable, readily penetrated the blood brain barrier, and
was well-tolerated in mice (Additional file 1: Data S3). The ef-
fect of PBT434 was initially tested in the mouse 6-OHDA
toxinmodel, where oral PBT434 (30mg/kg/day)was adminis-
tered 3 days after the toxin (Fig. 3a, b and Additional file 1:
Fig. S4). PBT434 prevented neuronal loss following 6-OHDA,
preserving up to 75% of the SNpc neurons remaining (both
Nissl and tyrosine hydroxylase (TH) positive neurons) after
the initial phase of cell death (p < 0.001). While rotational be-
havior was improved with both L-DOPA (20 mg/kg/day) and
PBT434, L-DOPAdid not prevent nigral damage.
Subsequent studies were only performed using the MPTP
intoxication model, which permitted higher throughput and
larger animal numbers per trial. The toxin-induced time
course of SNpc cell death caused by MPTP is characterized
by initial phase of rapid cell death, followed by a more grad-
ual cell loss continuing up to 21 days after the initial insult
[48–51, 65, 86]. We confirmed this pattern of cell loss in our
MPTP paradigm using stereological counting of SNpc neu-
rons on days 1, 3, 10 and 21 following administration of
toxin (Additional file 1: Fig. S4). To avoid possible interac-
tions with the toxin, PBT434 was administered to MPTP-
treated mice one-day post intoxication. Animals in the treat-
ment arm were gavaged once daily with PBT434 or its non-
metal binding analog PBT434-met, each at 30 mg/kg/day (a
dose which preliminary studies established was well toler-
ated, Additional file 1: Data S3). PBT434 was tested in 12
separate experiments. On average across these trials, MPTP
induced a 44% ± 4% depletion of SNpc neurons. The
PBT434-met analog control had no significant effect (Fig.
3c). Motor activity in MPTP treated mice was assessed at
21 days by pole test. We adopted the pole test for the MPTP
studies, as this task is sensitive to MPTP-induced denerv-
ation [44, 45, 61, 69]. When compared with vehicle alone
PBT434 significantly reduced MPTP-mediated motor defi-
cits in the pole test (p < 0.001; Fig. 3d).
Dose-response
In order to establish if a dose-response relationship existed,
we administered 1, 3, 10, 30 or 80 mg/kg PBT434 to MPTP-
challenged mice for 20 days, as described. SNpc neuron
number (Fig. 4a) and motor performance (pole test, Fig. 4b)
were assessed for each dose arm at day 21 post-intoxication.
The proportion of SNpc cells preserved increased incremen-
tally with increasing dose of PBT434 with significance be-
coming apparent at 3 mg/kg/day, and maintained at 10, 30
and 80 mg/kg/day. As the dose of PBT434 increased there
was a dose-dependent improvement motor performance on
the pole test, reaching significance at 30 mg/kg/day, and al-
most completely rescued at 80 mg/kg/day.
Nigro-striatal connectivity
Varicosities are the sites where the axons of SNpc neurons
synapse with neurons in the caudate/putamen. Typically,
Fig. 2 Inhibition of iron mediated α-synuclein (α-syn) aggregation.
Recombinant α-synuclein (186.6 μM) was incubated alone or in the
presence of equimolar concentrations of iron nitrate (iron = Fe (NO3)3),
PBT434 or PBT434-met. Thioflavin T (ThT) fluorescence was measured
(RFU = relative fluorescent units) every 30 min for 42 h. The lag-time
of aggregation was slowed by PBT434 (α-synuclein = 37 h,
α-syn + iron = 10.2 h, α-syn + iron + PBT434 = 16.60 h and
α-syn + iron + PBT434-met =7.9 h). a One Way ANOVA with
games-howell post hoc analysis (unequal variances on the lag-phases,
individual reaction wells (n = 5–6) showed that, α-syn + iron had
significantly faster aggregation than α-syn + iron + PBT434 (p = 0.02)
or α-syn alone (p = 0.04) but not α-syn + iron + PBT434-met (p = 0.49).
Lower panels: Electron micrographs of samples from each reaction
mixture were taken after 42 h (b; α- synuclein, no iron); c Increased fibril
formation in the presence of iron; d Diminished fibril formation in the
presence of PBT434; E) PBT434-met did not reduce the fibril formation
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in PD and in MPTP lesions there is substantial loss of
these synapses. At 21 days after MPTP intoxication, TH-
positive varicosities in vehicle treated animals were re-
duced by more than 50% compared with unlesioned mice
(p < 0.05). The number of TH- positive varicosities was
significantly higher in PBT434-treated animals at both 30
and 80 mg/kg when compared with untreated animals
(Fig. 4c, d). In a complementary study, we found that
MPTP treatment significantly reduced levels of the pre-
synaptic protein synaptophysin, and this lesion was abol-
ished by treatment with PBT434 (30 mg/kg/day) (Fig. 4e).
Effects of PBT434 upon toxin-mediated elevation of iron
We applied laser ablation inductively-coupled plasma
mass spectrometry (LAICPMS) [38, 39, 58] to
monitor the level and distribution of iron in the SN
of test animals. This technique, while providing more
information than manual microdissection, could not
discriminate between SN pars reticulata and SNpc.
Not to our knowledge reported previously, MPTP
challenge caused iron levels to rise in several brain
regions 21 days after the MPTP. Iron levels in the SN
were elevated by around 25% compared with the
control animals at day 21, and were normalized by
PBT434 treatment (30 mg/kg/day by oral gavage)
(Fig. 5a). Solution phase ICPMS applied to SNpc tis-
sue dissected manually from a separate MPTP/
PBT434 cohort confirmed these results, and found that
neither MPTP nor PBT434 significantly affected SNpc
copper levels (Additional file 1: Figure S5).
Oxidative stress markers
In MPTP lesioned animals, levels of the oxidative stress
marker 8-isoprostane in the SNpc were elevated to over
200% those of the unlesioned controls. 8-isoprostane
levels in the corresponding PBT434-treated cohort did not
rise significantly above control levels (Fig. 5c). Conversely,
DJ-1 levels were significantly increased by MPTP and fur-
ther elevated in PBT434-treated animals (Fig. 5d).
Effect of PBT434 upon MPTP-mediated elevation of
α -synuclein
MPTP intoxication in wild-type mice has been reported
to cause an increase in α-synuclein protein levels in the
SNpc [79, 89]. We found that MPTP induced a
Fig. 3 PBT434 prevents toxin induced cell loss and improves motor performance. a 6-OHDA injection resulted in the loss of 65% of the SNpc
neurons compared with unlesioned control animals. PBT434 administration commencing 3 days following intoxication and significantly preserved
neuron numbers compared with vehicle (p < 0.001, One-way ANOVA, Tukey Post Hoc). The number of neurons in an unlesioned mouse is
6124 ± 23. L-DOPA did not protect neurons against 6-OHDA toxicity. b Mice treated with PBT434 (30 mg/kg/day, N = 11 (P < 0.05) or L-DOPA
(15 mg/kg, P < 0.001, One-way ANOVA, Tukey Post Hoc) showed significantly fewer rotations than vehicle treated mice. c PBT434 (30 mg/kg/day
for twenty days) administered 24 h following intoxication with MPTP resulted in significantly reduced SNpc neuronal loss (*** P < 0.001, One-way
ANOVA, Tukey Post Hoc). PBT434-met 30 mg/kg/day (PBT434 without the metal binding site) does not protect against MPTP. d PBT434 treatment
resulted in improvement in motor performance in the Pole test (* P < 0.05, One-way ANOVA, Tukey Post Hoc). UL = unlesioned, VEH = standard
suspension vehicle without compound, PBT434-met = analogue of PBT434 without the metal binding
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significant and marked rise in α-synuclein levels in the
SNpc that persisted at day 21, and was abolished by con-
current PBT434 treatment (Fig. 5e).
Effect on ferroportin
In previous work we showed that iron accumulation in
an animal model of Parkinsonism was associated with
failure of the iron export apparatus [4, 5, 61]. Consistent
with previous reports [26], we found that MPTP caused
a profound reduction in levels of the iron export protein
ferroportin in the SNpc. Treatment with PBT434
(30 mg/kg/day for 20 days), prevented this and ferroportin
protein levels remained similar to those of unlesioned ani-
mals (Fig. 5f).
Fig. 4 Dose response effects of PBT434 on neuron number and TH - positive varicosities. The effects on SNpc neuron number and motor
function in response to escalating dose of PBT434 were assessed. 12–14 week old male C57BL/6 mice were lesioned using MPTP (60 mg/kg)
resulting in an average SNpc lesion size of 55%. Treatment with PBT434 at 1,3,10, 30 or 80 mg/kg/day commenced 24 h after induction of lesion.
a Mean number of SNpc neurons compared with the vehicle treated group (VEH)(±SEM). The proportion of SNpc cells rescued increased with
increasing dose of PBT434. 3 mg (P < 0.05), 10 mg (P < 0.01), 30 mg (P < 0.001) and 80 mg/kg/day (P < 0.001) doses prevented a significant
proportion of cell loss by day 21 (73 animals were studied from two separate MPTP experiments; One-way ANOVA paired with Games-Howell
post hoc test). The red dotted line indicates the normal value. b Pole test was undertaken at day 20 post intoxication to test motor performance.
As the dose of PBT434 increased there was a trend to improved turning behavior compared with the vehicle group while doses 30 mg/kg/day
(P < 0.05) and 80 mg/kg/day (P < 0.01) showed a significant 2.5–3 fold improvement in the time to turn. (One-way ANOVA paired with Games-
Howell post hoc test). The dashed line represents the average time taken by unlesioned animals to perform the task. c The abundance of tyrosine
hydroxylase-positive varicosities in the caudate putamen was assessed by stereology at day 21 following MPTP (N = 6–7 animals per treatment).
Following MPTP intoxication, TH -positive varicosities were reduced compared with unlesioned mice (* p < 0.05. One-way ANOVA, Tukey’s Post
hoc comparison). Treatment with 30 or 80 mg/kg of PBT434 significantly increased varicosity abundance compared with untreated mice. d Light
micrographs of the dorso-lateral tier of the caudate putamen showing individual tyrosine hydroxylase -positive varicosities (arrows), for unlesioned
animals (UL), MPTP lesioned vehicle treated (VEH) or following PBT434 treatment (scale bar = 25 μm). e Western blots of the dorsal tier of the
caudate putamen showed that treatment with PBT434 prevented the decline in levels of the presynaptic marker synaptophysin (SYNP), * p < 0.05,
One-way ANOVA, Tukey Post hoc comparison). TP = total protein, OD = optical density
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Effect of PBT434 in the α-synuclein transgenic (hA53T)
mouse
We tested whether the neuroprotective effects of
PT434 could be reproduced in a genetic model of
PD. The hA53T mutant α- synuclein transgenic
mouse has a subtle disease phenotype [12, 14, 31, 35,
72]. At 8 months of age, the hA53T mice exhibit de-
creased locomotion in the open field test compared
with wild type animals, and hindlimb clasping behav-
ior (Additional file 1: Figure S6), indicative of striatal
damage. This is accompanied by a modest but signifi-
cant decrease in the number of nigral neurons
Fig. 5 PBT434 improves iron level following MPTP lesion. 12–14 week old male C57BL/6 mice were lesioned using MPTP which resulted in a
lesion size 65–70% cell loss by day 21. MPTP lesioned mice were treated with vehicle (VEH) or PBT434 (30 mg/kg/day) from day 1 to day 21. a
Brain samples collected at day 21 were sectioned and scanned using laser ablation-inductively coupled plasma-mass spectrometry. Representative
images show Fe distribution in normal, unlesioned, wildtype (C57BL6) mouse brain, MPTP lesioned brain and MPTP + PBT434 treated brain. The
heat map quantifies the level of iron in the SN, which is indicated by the arrow. b The concentrations of Fe (mg/kg) in the substantia nigra (SN,
includes both compacta and reticulata) of the groups of mice were plotted onto a bar graph. MPTP injury causes a significant elevation in Fe in
the SN at day 21 (**p < 0.01, one-way ANOVA, Tukey post hoc) compared with unlesioned mice (UL) which was attenuated by PBT434 (* p < 0.05,
one-way ANOVA, Tukey post hoc). c PBT434 significantly prevented the MPTP induced elevation of 8-isoprostane within SN as measured by ELISA
(*P < 0.05, One-way ANOVA, Tukey Post Hoc). d Western blot was used to measure levels of levels of DJ-1 in the SN. Levels of DJ-1 were significantly
elevated with MPTP treatment in the absence of drug (VEH) and significantly further elevated with PBT434 (TP = Total Protein; OD = optical density;
***P < 0.001, One-way ANOVA, Tukey post hoc). The protein ran at the predicted molecular weight (24 kDa) as can be seen by comparing the position
of the proteins with the molecular weight ladder on the right of the image. e α-synuclein levels in mice administered MPTP or MPTP + PBT434
(30 mg/kg/day, were compared with unlesioned controls; UL). SN tissue samples were homogenized to form a lysate, which was assayed by Western
blot and quantitated by optical density (OD) normalized to total protein (TP, Ponceau). The protein ran at the predicted molecular weight 14 kDa
compared to with the molecular weight ladder on the right of the image. In MPTP lesioned mice α-synuclein was significantly elevated by day 21
(**P < 001, one-way ANOVA, Tukey post hoc). α-synuclein protein levels were significantly lower with PBT434 treatment (*P < 0.05, one-way ANOVA,
Tukey post hoc) compared with Vehicle treated animals. f Western blot of MPTP lesioned mice showed a significant reduction in levels of ferroportin
protein which were decreased 21 days after the lesion (*P < 0.05). The protein ran at slightly less the predicted molecular weight 63 kDa compared to
with the molecular weight ladder on the right of the image. Ferroportin protein levels were significantly higher with PBT434 treatment (*P < 0.05)
compared with the vehicle treated animals but not different to unlesioned mice (one-way ANOVA, Tukey post hoc)
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between 4 and 8 months of age. Long term (4 months)
treatment with PBT434 incorporated into the animal
feed (to achieve an average dose of 30–37 mg/kg/day)
from 4 months of age significantly preserved SNpc neuron
number (Fig. 6a) accompanied by increased total move-
ments in the open field test and reduced clasping behavior
(Additional file 1: Figure S6). In the Tg mice at 8 months,
four months of PBT434 treatment reduced SN iron levels
by 15% (Fig. 6b) PBT434 treatment did not alter the levels
of soluble α- synuclein (Fig. 6c). but significantly de-
creased the nigral insoluble (urea extracted) α- synuclein
(Fig. 6d). and significantly increased nigral ferroportin
levels (Fig. 6e).
Cerebral spinal fluid (CSF) biomarkers
In a small exploratory study, CSF collected post-mortem
from dogs undergoing a 28 day dose-tolerability study of
PBT434 was assayed for soluble α-synuclein a dose
dependent trend (non-significant) in the reduction of α-
synuclein was observed (Fig. 7a). To further investigate
this phenomenon in a more controlled environment,
cannula were surgically implanted into the lateral ventri-
cles of rats (n = 10). CSF was sampled before and after
gavage with 30 mg/kg PBT434 and analyzed by Western
blot for the presence of α-synuclein. At four hours but
not at one hour, α-synuclein levels were significantly
lower than baseline (p = 0.05, Fig. 7b).
Fig. 6 PBT434 modulates α-synuclein transgenic animals. hA53T α-synuclein Tg mice consumed an average of 37 mg/kg/day in animal chow of
PBT434 from 4 months of age for 4 months. a PBT434 preserved SNpc neurons (** P < 0.01, one-way ANOVA, Tukey post hoc); b PBT434 decreased SN
iron measured by mass spectrometry (*P < 0.05, T-Test). SN tissue samples were homogenized to form a lysate, which was assayed by western blot
and quantitated by optical density (OD) normalized to total protein (TP, Ponceau). c PBT434 did not reduced levels of the SDS soluble fraction
of α- synuclein in the SN (Western blot, urea soluble fraction); d PBT434 reduced levels of the urea soluble fraction of α- synuclein in the SN
(** p < 0.01; T-Test); E) PBT434 treatment increased SN ferroportin levels (*P < 0.05, T-Test)
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Discussion
PBT434 is a novel, orally bioavailable, moderate iron af-
finity 8-hydroxyquinazolinone which is being developed
for treatment of Parkinsonian conditions. We adapted
commonly used Parkinsonian toxin models and the hA53T
α-synuclein transgenic mouse to investigate the therapeutic
potential of PBT434 to slow or prevent progressive neuro-
degeneration in PD. We found that PBT434 preserved
SNpc neuron number in animal models of SNpc degener-
ation and synucleinopathy which translated to improved
motor function accompanied by reduced levels of α-
synuclein and a reduction in markers of oxidative stress.
The observation that the analog of PBT434, (PBT434-met),
in which the metal binding site was blocked, had no pro-
tective effect, is consistent with the proposed metal-centric
mechanism of action.
Although there is an accumulation of iron in the neu-
rons of the SN in PD [71], it may be simplistic to
characterize the condition as a disease of iron overload
analogous to hemochromatosis or thalassemia in which
potent chelators are required for clinical effect [75]. Evi-
dence suggests rather, that subtle alterations to mecha-
nisms maintaining metal homeostasis are disrupted,
leading to anatomically localized deficits and surpluses
[4–6, 61]. Inevitably this results in an increase in the
weakly bound or labile metal pool [7, 8], including iron,
a potent generator of free-radicals. Recent findings have
placed iron close to the center of pathological events
[5, 21]. For instance, it has been recently demonstrated
that cellular reactive oxygen species production by α-
synuclein oligomers is entirely dependent on the pres-
ence of free metal ions, as addition of metal chelators
could block oligomer-induced reactive oxygen species
production and prevent oligomer-induced neuronal death
[23]. Furthermore, oxidative stress, a feature of both
disease and aging is now understood to be sufficient in
of itself to engender the deterioration in the performance
of the iron trafficking apparatus which is manifested in ab-
errant iron distribution [21, 68, 76].
With a Kd around 1010 the affinity of PBT434 for iron
is considered moderate compared with physiological iron
ligands such as transferrin (Kd 1023) [3] and orders of
magnitude lower than iron chelators in clinical use such
as deferiprone Kd 1035) [55]. The significantly lesser efflux
of iron from cultured cells engendered by PBT434 com-
pared with deferiprone reflects the widely differing Kds
and physicochemical properties of the two drugs. As a
corollary, no significant effect on global brain iron levels
in normal intact mice was observed within the effective
dose range of PBT434.
We assessed the efficacy of PBT434, administered as a
single daily oral dose, in attenuating the neurotoxic cas-
cade following intoxication with the Parkinsonian toxins
6-OHDA and MPTP. As SNpc neurons continue to die
for weeks after intoxication with both 6-OHDA and
MPTP efficacy [48, 50, 51, 65, 86], we elected to evaluate
the extent of preservation of SNpc neurons at 21 days as
the primary measure of efficacy. MPTP has the advan-
tage of being able to produce larger numbers of uni-
formly lesioned animals, therefore most the studies were
undertaken using the MPTP model. By delaying admin-
istration of PBT434 until the toxin is known to have
been cleared [47, 90] we obviated the possibility of false
positive results caused by incidentally neutralizing the
toxin, by blocking its uptake, or by preventing its
Fig. 7 α-synuclein levels in CSF of dogs and rats following PBT434
treatment. α-synuclein was collected and quantified from CSF of
dogs and rats following PBT434 treatment. a α-synuclein levels of
CSF collected from dogs following 28 days exposure to PBT434 at
various doses. α-synuclein levels detected by enhanced Western blot
decline in the 10 mg/kg, did not reach significance (one-way ANOVA,
Tukey post hoc). b Cannula were implanted into the lateral ventricles
of wild type rats and CSF was sampled before and after gavage with
30 mg/kg/day PBT434. Western blot for the presence of showed a
significant decrease in α-synuclein at 4 h but not at 1 h (* P < 0.05,
one-way ANOVA, Tukey post hoc)
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conversion to MPP+ [56]. The 6-OHDA toxin has simi-
lar potential for interactions with test compounds, there-
fore PBT434 administration was delayed until 72 h after
intra-nigral injection of 6-OHDA. 6-OHDA lesion size
being directly related to the rotational behavior
(Additional file 1: Figure S4). Further stringency was in-
troduced by selecting only those mice that rotated 200–
450 times an hour. The presence of an MPTP-induced
lesion is related to motor dysfunction although unlike 6-
OHDA, no direct correlation has been shown between
lesion size and motor performance [45, 69]. We found
the MPTP-affected brain to be sensitive to dose of
PBT434; incremental improvements in SNpc neuron via-
bility reflected in similarly dose-dependent improve-
ments in motor function (Fig. 4). While increasing
survival of SNpc neurons is important, in order for func-
tion to be maintained, connectivity between these neu-
rons and their synaptic partners in the striatum is
required. PBT434 preserved nigro-striatal synaptic cir-
cuitry, reflected in the abundance of terminal varicosi-
ties. The maintenance of nigro-striatal synaptophysin
protein at levels seen in intact animals supports the
conclusion that preservation of connectivity is likely a
major contributor to the improvement in motor function
observed with PBT434.
As ferroportin is the primary iron exporting protein,
the precipitous drop in ferroportin levels following the
MPTP insult may be sufficient to explain the rise in
SNpc iron [60]. Presumably, the effect of PBT434 in
sustaining ferroportin levels is a beneficial consequence
of its neuroprotective effect although a direct effect
cannot yet be ruled out.
It has been reported that iron, copper and dopamine
under oxidizing conditions each foster the aggregation
of α-synuclein and the formation of toxic soluble oligo-
meric species [19, 43, 63]. The sharp rise in α-synuclein
levels following MPTP treatment is well documented
[89]. We speculate that in the MPTP model PBT434
modulates α-synuclein expression via the iron responsive
element on the 5′ untranslated region of its mRNA by
sequestering weakly bound cellular iron. It has been re-
ported that α-synuclein itself has ferri-reductase activity
capable of reducing Fe III to Fe II which lends further
weight to the argument that its expression is likely finely
tuned to the presence of iron [22]. The reduction in α-
synuclein in the A53T mouse cannot be explained by al-
tered expression, as the A53T transgene does not encode
the IRE sequence which would permit it to respond to al-
terations in cellular iron levels. As noted previously, over
the course of treatment the level of nigral iron in the
transgenic mice did decline by a modest but significant
15%. We hypothesize that this reflects an enlarged pool of
labile or weakly bound iron previously identified as a
feature of the Parkinsonian brain [54], which may
interact aberrantly with α-synuclein to promote aggre-
gation and deposition.
We postulated that if the ability of PBT434 to prevent
the elevation in α-synuclein levels following MPTP in
wild type mice was due to its effect on the labile iron
pool, that same effect might also be detectable in healthy
animals. Examination of samples of post-mortem CSF
from healthy dogs treated with PBT434 for 28 days
showed a significant dose-dependent reduction in α-
synuclein, an effect also observed in rats fitted with an
indwelling ventricular catheter, consistent with the hy-
pothesis that PBT434 modulates α-synuclein expression
at the translational level. This finding raises the possibil-
ity that CSF α-synuclein may be of value as a marker of
target engagement in the clinical setting. There is con-
siderable debate and some justifiable skepticism sur-
rounding the use of biomarkers like CSF α-synuclein as
indices of disease progression [52], however, such bio-
markers, especially if they are demonstrably linked to
drug mechanism of action, may be judiciously applied to
the evaluation of target engagement for new drugs,
assisting in the early phases of clinical development.
The potential for oxidative damage is increased when
the normally tight control over the trafficking of redox
active metals is impaired. Such impairment may be re-
lated to altered activity of the metal trafficking apparatus
[8, 80] or more indirectly through impaired function of
iron dependent enzymes of the (mitochondrial) oxidative
phosphorylation apparatus and enzymes such as hypoxia
inducible factor (HIF) which have roles in the adaptation
to hypoxic or oxidative stress [84]. The marked reduc-
tion in 8-isoprostane levels observed in the MPTP
treated mice following treatment with PBT434 indicates
that its anti-oxidant properties translate to the in vivo
milieu.
Defects in the gene encoding the protein deglycase
DJ-1 are a cause of autosomal recessive early-onset
Parkinson’s disease [37]. In pro-oxidative conditions,
DJ-1, also known as Park7, has been shown to inhibit
the aggregation of α-synuclein, to function as a redox-
sensitive chaperone [83], as a sensor for oxidative
stress and as a mitochondrial pacemaker minimizing
oxidative stress associated with dopamine secretion
[37]. It has also been shown to bind metals and pro-
tect against metal mediated toxicity [13]. The effect of
PBT434 upon this multifaceted protein is particularly
intriguing because intoxication with MPTP causes a
substantial rise in DJ-1 which is further enhanced by
treatment with PBT434. Further investigation will re-
veal the role of DJ-1 in the response to MPTP and
where that pathway intersects with the mechanism of
action of PBT434. In vitro, DJ-1 has been shown to in-
hibit the toxicity of A53T α-synuclein [91, 92]. In our
hands, by the age of 8 months, there was as yet scant
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evidence of acute oxidative damage in the A53T mice
similar to the MPTP model, nor did we observe alter-
ations to the levels of DJ-1. Literature sources suggest
that any such damage may be more subtle, manifested
in oxidation of mitochondrial proteins [66] and in particu-
lar in post translational modifications of α-synuclein itself
such as oxidation or nitration [88].
Conclusions
Genetic and experimental evidence strongly implicate α-
synuclein in the etiology of Parkinson’s disease, recom-
mending this protein as a plausible target for potential dis-
ease modifying therapies. As understanding of the role of
iron in the pathological process in PD evolves, evidence is
emerging that α-synuclein levels may be modulated by se-
lective targeting of this ubiquitous biometal. PBT434 was
developed to exploit this therapeutic niche and in addition
to its potential utility in the clinic will be a valuable tool
for studying the role of metals in modulating α-synuclein
levels, the role of oxidative stress as an initiator and per-
petuator of the nigral lesion and the involvement of other
components of the neuronal iron trafficking apparatus.
Treatments currently available for PD and the atypical
Parkinsonian conditions at best provide limited symptom-
atic relief and do not alter disease progression. The benefi-
cial effects of PBT434 on motor function, neuropathology
and biochemical markers of disease state in three different
animal models of PD suggest disease modifying potential.
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